Tumeurs de l'ovaire et CA 125 en 2006

Lambaudie, Éric; Collinet, Pierre; Vinatier, D.

doi:10.1016/j.gyobfe.2006.01.026

Cited by 4 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CA-125 has a sensitivity of 80% and a specificity of 97% in epithelial cancer (stage III or IV, ( Figure 1)). However, its sensitivity is around 30% in stage I cancer, its increase is linked to www.intechopen.com several physiological phenomena and it is also detected in benign situations 15 . CA-125 is particularly useful for at-risk population diagnosis and following disease progression during therapeutic treatment.…”

Section: Ovarian Cancermentioning

confidence: 99%

MALDI-MSI and Ovarian Cancer Biomarkers

Longuespée

Boyon²,

Kerdraon³

et al. 2012

Advances in Cancer Management

View full text Add to dashboard Cite

Section: Ovarian Cancermentioning

confidence: 99%

MALDI-MSI and Ovarian Cancer Biomarkers

Longuespée

Boyon²,

Kerdraon³

et al. 2012

Advances in Cancer Management

View full text Add to dashboard Cite

“…CA 125 has a sensitivity of 80% and a specificity of 97% in epithelial cancer (stage III or IV), but the sensitivity is around 30% in stage I and its increase can be linked to several physiological phenomena and also detected in benign situations. 2 CA 125 is very useful in the case of risk populations' diagnosis or to follow the illness evolution during the therapeutic treatment. In this context, CA 125 is insufficient as a single biomarker for ovarian cancer diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Specific MALDI Imaging and Profiling for Biomarker Hunting and Validation: Fragment of the 11S Proteasome Activator Complex, Reg Alpha Fragment, Is a New Potential Ovary Cancer Biomarker

et al. 2007

View full text Add to dashboard Cite

MALDI imaging mass spectrometry represents a new analytical tool to directly provide the spatial distribution and relative abundance of proteins in tissue. Twenty-five ovary carcinomas (stages III and IV) and 23 benign ovaries were directly analyzed using MALDI-TOF MS. The biomarker with the major prevalence (80%) has been fully identified using MALDI MS and nanoESI MS and MS/MS after separation by RP-HPLC and trypsin enzymatic digestion. This marker with an m/z of 9744 corresponds to 84 amino acid residues from the 11S proteasome activator complex, named PA28 or Reg-alpha. Validation of this marker has been performed using MALDI imaging, classical immunocytochemistry with an antibody raised against the C-terminal part of the protein, specific MALDI imaging, and Western blot analysis. The validation, using immunocytochemistry, confirmed the epithelial localization of this fragment with nucleus localization in benign epithelial cells and a cytoplasmic localization in carcinoma cells. This indicates that this antibody could be used to discriminate the borderline tumor cases. At this point, a multicentric study needs to be conducted in order to clearly establish the potential of this biomarker. Taken together these studies reflect that direct tissue analysis and specific MALDI imaging strategies facilitate biomarker hunting and validation which can be named pathological proteomics.

show abstract

“…But the determination of the benignity or malignancy of a tumor during preoperative treatment is an important step in the management of these patients. According to a bundle of arguments: the patient's age, menopause, clinical characteristics, imaging and the dosage of CA125 helps reduce false diagnoses of cancers (8) .…”

Section: Discussionmentioning

confidence: 99%

Giant Ovarian Mucinous Cystadenoma Discussion of One Case with Review of the Literature

Haderi¹,

Berrada²,

Bamohamed³

et al. 2017

IAM

View full text Add to dashboard Cite

The giant mucinous cystadenoma is a rare ovarian neoplasm with benign biological behavior, characterized by a large tumor volume. Delayed diagnosis can cause serious complications such as rupture, infection and malignant transformation. In this article, and based on literature review, we will discuss the case of a giant mucinous cystadenoma in a 54-yearold woman treated surgically by a total hysterectomy with bilateral adnexectomy.

show abstract

Tumeurs de l'ovaire et CA 125 en 2006

Cited by 4 publications

References 56 publications

MALDI-MSI and Ovarian Cancer Biomarkers

MALDI-MSI and Ovarian Cancer Biomarkers

Specific MALDI Imaging and Profiling for Biomarker Hunting and Validation: Fragment of the 11S Proteasome Activator Complex, Reg Alpha Fragment, Is a New Potential Ovary Cancer Biomarker

Giant Ovarian Mucinous Cystadenoma Discussion of One Case with Review of the Literature

Contact Info

Product

Resources

About